Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 301

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction

Open access
Erlinge, David, Omerovic, Elmir, Fröbert, Ole, Linder, Rikard, Danielewicz, Mikael, Hamid, Mehmet, Swahn, Eva, Henareh, Loghman, Wagner, Henrik, Hårdhammar, Peter, Sjögren, Iwar, Stewart, Jason, Grimfjärd, Per, Jensen, Jens, Aasa, Mikael, Robertsson, Lotta, Lindroos, Pontus, Haupt, Jan, Wikström, Helena, Ulvenstam, Anders, Bhiladvala, Pallonji, Lindvall, Bo, Lundin, Anders, Tödt, Tim, Ioanes, Dan, Råmunddal, Truls, Kellerth, Thomas, Zagozdzon, Leszek, Götberg, Matthias, Andersson, Jonas, Angerås, Oskar, Östlund, Ollie, Lagerqvist, Bo, Held, Claes, Wallentin, Lars, Scherstén, Fredrik, Eriksson, Peter, Koul, Sasha, James, Stefan · 2017 · New England Journal of Medicine

Abstract

BACKGROUNDThe comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y 12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors. METHODSIn this multicenter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y 12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors.The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access.The primary end point was a composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-up. RESULTSA total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial.At 180 days, a primary end-point event had occurred in 12.3% of the patients (369 of 3004) in the bivalirudin group and in 12.8% (383 of 3002) in the heparin group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.10; P = 0.54).The results were consistent between patients with STEMI and those with NSTEMI and across other major subgroups.Myocardial infarction occurred in 2.0% of the patients in the bivalirudin group and in 2.4% in the heparin group (hazard ratio, 0.84; 95% CI, 0.60 to 1.19; P = 0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ratio, 1.00; 95% CI, 0.84 to 1.19; P = 0.98), definite stent thrombosis in 0.4% and 0.7%, respectively (hazard ratio, 0.54; 95% CI, 0.27 to 1.10; P = 0.09), and death in 2.9% and 2.8%, respectively (hazard ratio, 1.05; 95% CI, 0.78 to 1.41; P = 0.76). CONCLUSIONSAmong patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy.(Funded by the Swedish Heart-Lung Foundation and others; VALIDATE-SWEDEHEART Clinical-TrialsRegister.eu number, 2012-005260-10; ClinicalTrials.govnumber, NCT02311231.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1706443

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 301

Metadata

Authors
Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., Swahn, E., Henareh, L., Wagner, H., Hårdhammar, P., Sjögren, I., Stewart, J., Grimfjärd, P., Jensen, J., Aasa, M., Robertsson, L., Lindroos, P., Haupt, J., Wikström, H., Ulvenstam, A., Bhiladvala, P., Lindvall, B., Lundin, A., Tödt, T., Ioanes, D., Råmunddal, T., Kellerth, T., Zagozdzon, L., Götberg, M., Andersson, J., Angerås, O., Östlund, O., Lagerqvist, B., Held, C., Wallentin, L., Scherstén, F., Eriksson, P., Koul, S., & James, S.
Venue
New England Journal of Medicine
Published
2017-09-21
Volume
377
Issue
12
Pages
1132-1142
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2745712984
Cited by
301
References
20
FWCI
26.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.